-
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
23 Apr 2024 10:17 GMT
… and Drug Administration as a first-line treatment for … Phase 3 trial with tislelizumab versus docetaxel that enrolled … 17 potentially registration-enabling trials with tislelizumab, of … approvals and commercializing pharmaceutical products and its …
-
Hyundai to advance cancer study plans for niclosamide-based drug
22 Apr 2024 17:20 GMT
… Phase I/IIa trials for several hard-to-treat … combination therapy, or docetaxel alone. The combination treatment was found to … the docetaxel-treated group.
The Phase I/IIa trial will … to the US Food and Drug Administration (FDA) to treat monkeypox. …
-
Hyundai Bioscience announces its successful result from a preclinical study of a Niclosamide-based oral anticancer drug to treat triple-negative breast cancer
22 Apr 2024 13:02 GMT
… anticancer agent with Docetaxel was conducted on animals … of these preclinical results, stating, "This is the … of drug resistance and metastasis that make cancer treatment difficult.… is a biotechnology company that develops new drugs based on …
-
Tecentriq, Cabometyx May Not Improve Survival Over Chemo in NSCLC
23 Apr 2024 22:04 GMT
… Neal, associate professor of medicine, Division of Oncology at … said Neal. “The one drug that's approved in … But it remains the FDA-approved treatment in that second line … plus Cabometyx (cabozantinib) versus docetaxel among patients with metastatic NSCLC …
-
Ferring Launches 3 New Clinical Trials for Marketed Bladder Cancer Gene Therapy Adstiladrin
18 Apr 2024 23:01 GMT
… consisting of gemcitabine and docetaxel or an immunotherapy … phase 4 clinical trial that will investigate retreatment … medical officer of Ferring Pharmaceuticals, said in a statement.1 “These new trials … /fda-approves-first-gene-therapy-treatment-high-risk …
-
Tislelizumab Earns European Approval in Non–Small Cell Lung Cancer
23 Apr 2024 17:43 GMT
… receive tislelizumab following treatment with prior targeted therapies … phase 3 RATIONALE 303 trial (NCT03358875), which … European Medicine Agency’s Committee for Medicinal Products for … al. Tislelizumab versus docetaxel in patients with previously …
-
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
18 Apr 2024 13:00 GMT
… ONCT-534 program. The drug has been well tolerated so … a potential treatment for patients with mCRPC with unmet medical need … zilovertamab in combination with docetaxel in patients with metastatic … trials; the risk that interim results of a clinical trial …
-
EC approves BeiGene’s tislelizumab for three NSCLC indications
23 Apr 2024 18:44 GMT
… (NCT03663205) trials, which evaluated tislelizumab combination treatment in the … NSCLC compared to treatment with docetaxel.
The most commonly … the parent company of Pharmaceutical Technology.
Access the … in March, the European Medicines Agency (EMA) accepted …
-
Analysis of Ionomic Profiles of Spinal Cords in a Rat Model with Bone Cancer Pain
23 Apr 2024 12:42 GMT
… the currently available therapeutic medicines.3 Furthermore, BCP … mediated protective effects against docetaxel-induced adverse peripheral … al reported that Se treatment significantly decreased fibromyalgia … Arabidopsis thaliana. Nat Biotechnol. 2003;21(10): …
-
EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer
20 Apr 2024 12:31 GMT
… National Health and Medical Research Council Investigator Grant … for cancer research. Pharmaceutics. 2020;12(12). doi … antibody conjugated docetaxel loaded PLGA nanoparticles into … FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment …